XCUR Quote, Financials, Valuation and Earnings

Electromed has a net margin of -165.8% compared to Exicure's net margin of 10.05%. Exicure's return on equity of -195.77% beat Electromed's return on equity of 15.62%.

Exicure has a consensus price target of --, signalling downside risk potential of -0.7%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could fall by -2.94%. Given that Electromed has more downside risk than Exicure, analysts believe Exicure is more attractive than Electromed.

Exicure has a beta of 3.808, which suggesting that the stock is 280.755% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Exicure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Exicure quarterly revenues are $500K, which are smaller than Electromed quarterly revenues of $14.7M. Exicure's net income of -$1.1M is lower than Electromed's net income of $1.5M. Notably, Exicure's price-to-earnings ratio is -- while Electromed's PE ratio is 47.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure is -- versus 5.31x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -165.8% compared to Exicure's net margin of -10.5%. Exicure's return on equity of -195.77% beat Myomo's return on equity of -84.04%.

Exicure has a consensus price target of --, signalling downside risk potential of -0.7%. On the other hand Myomo has an analysts' consensus of -- which suggests that it could grow by 25.68%. Given that Myomo has higher upside potential than Exicure, analysts believe Myomo is more attractive than Exicure.

Exicure has a beta of 3.808, which suggesting that the stock is 280.755% more volatile than S&P 500. In comparison Myomo has a beta of 1.719, suggesting its more volatile than the S&P 500 by 71.909%.

Exicure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Exicure quarterly revenues are $500K, which are smaller than Myomo quarterly revenues of $9.2M. Exicure's net income of -$1.1M is lower than Myomo's net income of -$966.4K. Notably, Exicure's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure is -- versus 8.91x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -165.8% compared to Exicure's net margin of -4291.67%. Exicure's return on equity of -195.77% beat Catheter Precision's return on equity of -65.84%.

Exicure has a consensus price target of --, signalling downside risk potential of -0.7%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 335.73%. Given that Catheter Precision has higher upside potential than Exicure, analysts believe Catheter Precision is more attractive than Exicure.

Exicure has a beta of 3.808, which suggesting that the stock is 280.755% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.184, suggesting its less volatile than the S&P 500 by 118.441%.

Exicure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Exicure quarterly revenues are $500K, which are larger than Catheter Precision quarterly revenues of $96K. Exicure's net income of -$1.1M is higher than Catheter Precision's net income of -$4.1M. Notably, Exicure's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure is -- versus 1.22x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -165.8% compared to Exicure's net margin of -17.98%. Exicure's return on equity of -195.77% beat Xtant Medical Holdings's return on equity of -35.98%.

Exicure has a consensus price target of --, signalling downside risk potential of -0.7%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 332.69%. Given that Xtant Medical Holdings has higher upside potential than Exicure, analysts believe Xtant Medical Holdings is more attractive than Exicure.

Exicure has a beta of 3.808, which suggesting that the stock is 280.755% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Exicure has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exicure pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Exicure quarterly revenues are $500K, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Exicure's net income of -$1.1M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Exicure's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exicure is -- versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.